About Scilex Holding Company
https://www.scilexholding.comScilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain.
CEO
Jaisim Shah
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : C
Price Target
About Scilex Holding Company
https://www.scilexholding.comScilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $10.56M ▲ | $193.74M ▲ | $-257.23M ▼ | -2.44K% ▼ | $-22.17 ▼ | $-254M ▼ |
| Q2-2025 | $9.9M ▲ | $27.13M ▼ | $-86.06M ▼ | -869.65% ▼ | $-7.42 ▼ | $-40.34M ▼ |
| Q1-2025 | $5M ▼ | $31.52M ▼ | $-26.08M ▼ | -521.18% ▼ | $-2.26 ▼ | $-22.6M ▼ |
| Q4-2024 | $14.9M ▲ | $38.59M ▲ | $-6.46M ▼ | -43.36% ▼ | $-1.23 ▼ | $-5.17M ▼ |
| Q3-2024 | $14.44M | $30.59M | $-4.39M | -30.4% | $-1.21 | $-2.81M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $878K ▼ | $275.88M ▲ | $455.6M ▲ | $-176.94M ▲ |
| Q2-2025 | $4.1M ▼ | $83.75M ▲ | $332.74M ▲ | $-248.99M ▼ |
| Q1-2025 | $5.8M ▲ | $78.98M ▼ | $290.46M ▲ | $-211.48M ▼ |
| Q4-2024 | $3.27M ▲ | $92.95M ▼ | $285.59M ▼ | $-192.64M ▲ |
| Q3-2024 | $77K | $100.43M | $311.75M | $-211.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-257.82M ▼ | $8.23M ▲ | $-152K ▲ | $-11.3M ▼ | $-3.22M ▼ | $8.53M ▲ |
| Q2-2025 | $-44.05M ▼ | $7.05M ▲ | $-153K ▲ | $-8.6M ▼ | $-1.7M ▼ | $7.05M ▲ |
| Q1-2025 | $-26.08M ▼ | $6.01M ▲ | $-395K ▼ | $-3.08M ▲ | $2.53M ▲ | $5.86M ▲ |
| Q4-2024 | $-6.46M ▼ | $2.53M ▼ | $-195K ▲ | $-7.18M ▼ | $-4.84M ▼ | $2.38M ▼ |
| Q3-2024 | $-4.39M | $5.11M | $-2.18M | $-4.48M | $-1.55M | $4.96M |
CEO
Jaisim Shah
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : C